Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion
about
Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphomaGene mutations and actionable genetic lesions in mantle cell lymphoma.Bruton's Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats.Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma
P2860
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion
@ast
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion
@en
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion
@nl
type
label
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion
@ast
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion
@en
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion
@nl
prefLabel
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion
@ast
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion
@en
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion
@nl
P2860
P3181
P356
P1476
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion
@en
P2093
Stephen E Spurgeon
P2860
P304
P3181
P356
10.1177/2040620715592569
P407
P577
2015-10-01T00:00:00Z